Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations'), we would like to inform ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved unaudited results for the quarter and half year ended 30 September 2025. Revenue from operations for Q2 FY26 rose to ₹946.82 lakh, up from ₹864.90 lakh in Q1 FY26 and ₹807.49 lakh in Q2 FY25 (about 17% year-on-year growth). The company swung back to a small profit of ₹14.96 lakh in Q2 from a loss of ₹74.11 lakh in the previous quarter, with EPS of ₹0.20. However, for the half year as a whole, the company is still in the red with a loss of ₹59.15 lakh, and accumulated losses have pushed its net worth deep into negative territory at minus ₹257.18 lakh. Operating cash flow for H1 turned negative at minus ₹33.93 lakh versus a positive ₹217.32 lakh a year ago, and cash balances fell from ₹264.69 lakh to ₹120.89 lakh. The board also reconstituted various board committees.
Short-term, Q2 turnaround in profitability and revenue growth are positive, but the deeply negative net worth, negative half-year PAT, and worsening operating cash flow raise serious concerns about the company's financial stability. Shareholders should watch closely for any signs of distress, fundraising, or restructuring; the stock may remain volatile.